SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

A sharp AMP price and volume surge has renewed attention, with traders pointing to Flexas European expansion and broader payment-network plans as potential catalysts. Bullish posts frame the developments as signs of future adoption, while skeptics question whether they will translate into meaningful usage and note AMPs history of fading rallies.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

QNTs sharp rally is being attributed by traders to a reported QuantThe Clearing House initiative involving interoperability for tokenized bank deposits. The community sees it as a potential institutional-use-case catalyst and points to QNTs limited supply, while others caution that the move may be overheated and vulnerable to a pullback.

XYO is the cryptographic proof layer for the real world, collecting, validating, and delivering physical-world data to AI, robotics, Web3, and enterprise systems. XYO, the original Decentralized Physical Infrastructure Network (DePIN), has been operating since 2018 and now has more than 10 million nodes worldwide.   At the core of XYO is XYO Layer One, a scalable data blockchain built to support high-volume data industries such as AI, robotics, location intelligence, and real-world asset (RWA) systems. Designed for high throughput and low transaction costs, it gives these data-intensive applications the capacity to process and validate information across massive datasets. XYO Layer One anchors XYO's Proof of Location and Proof of Origin technologies, establishing a verified origin, precise timing, and trusted source behind every piece of data. This verified data directly feeds the XYO AI SDK, a product built by XYO to provide accessibility for developers to build AI-powered applications, autonomous agents, robotics integrations and more using real-world data.  XYO employs a unique dual-token model:  XYO Token: An externally traded token supporting the DePIN ecosystem, rewards, staking, and governance, enhancing overall ecosystem value and scarcity.   XL1 Token: Internal to the XYO Layer One blockchain, facilitating transactions, gas fees, and other blockchain-specific use cases.  The dual-token economics are strategically designed to increase scarcity and promote sustainable growth.   The XYO token has been available on major exchanges since 2018. Major exchanges include Coinbase and Revolut. The XL1 token is now also available.

XYO Network

XYO is drawing attention on bullish hopes for a technical breakout as traders watch resistance and the 200-day moving average, but skeptics point to weak volume and a history of sharp rallies giving back their gains. No confirmed new catalyst is established in the discussion.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiaks scheduled Phase 3 DAYBREAK topline readout for Zenkuda and KSI-501 in wet AMD is the dominant focus, with traders treating the results as a high-risk, binary catalyst. Some expect positive data and a rally, while others cite the trials uncertainty and Kodiaks prior setbacks as reasons to reduce exposure or brace for a sharp downside reaction.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cashs sharp rally and subsequent volatile price action are driving attention, with traders citing CME futures access and a Grayscale filing as possible catalysts. Bulls see room for a breakout and point to BCHs relative strength, while skeptics question the moves staying power and warn of further downside.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin Trust ETF

IBIT is drawing attention as Bitcoin rebounds, with traders pointing to renewed spot Bitcoin ETF inflows and short covering while many say they are buying dips. Others caution that the rally may be vulnerable to a pullback, framing the move as a possible bull trap or technical resistance test.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Traders are focused on Compounds institutional-market push and plans to expand into tokenized-asset lending, viewing them as potential longer-term growth drivers alongside the tokens limited supply. Bulls anticipate a catch-up move if DeFi and altcoins strengthen, while skeptics point to COMPs weak performance versus peers and question whether the initiatives will create lasting demand.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

ICP is drawing attention after a rebound and attempted breakout following a prolonged stretch of weak price action. Bulls point to reported Pakistan government applications and ICPs AI and decentralized-cloud ambitions as signs of adoption, while skeptics say the token still struggles to sustain momentum and needs clearer proof of demand.

Grayscale Ethereum Trust (ETH) operates as open-end investment company. Its investment objective is for the shares to reflect the value of ETH held by the trust. The company was founded on December 13, 2017 and is headquartered in Stamford, CT.

Grayscale Ethereum Staking Mini ETF - Common units of fractional undivided beneficial interest

Grayscale Ethereum Mini Trust

Ethereums rebound and attempts to break out are drawing attention, alongside broader crypto-market moves. Traders are split between seeing renewed momentum and warning that thin volume, macro uncertainty, or a pullback could undermine the advance.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilio is under pressure after HSBC downgraded the stock, arguing that excitement around Metas Muse AI agents may overstate Twilios ability to capture revenue if it mainly supplies commoditized connectivity and authentication while Meta keeps the higher-value AI layer in-house. Bulls counter that broader AI-agent adoption could still drive more calls, texts and messaging through Twilios platform.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Johnson & Johnson is repeatedly named by traders as a possible buyer of Sellas Life Sciences, with speculation linked to Sellass pending REGAL trial results and J&Js oncology ambitions; no deal is confirmed. The conversation also includes bullish reactions to JNJs recent strength, alongside some technical concerns.

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsAbbVie continues to diversify its portfolio into neuroscience and aesthetics to offset the loss of patent exclusivity for older drugs...

Johnson & Johnson Clinical Trials Show Progress Across Key Therapies

Johnson & Johnson shares key clinical trial results for Tremfya in psoriatic arthritis and five-year Carvykti data in multiple myeloma.read more...

Johnson & Johnson announces TREMFYA (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study

Johnson & Johnson announces TREMFYA (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study Johnson & Johnson announces TREMFYA (guselkumab) is the first and only IL-23 inhibitor to show...

Single infusion of CARVYKTI (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma

Single infusion of CARVYKTI (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma Single infusion of CARVYKTI (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in...

Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?

AbbVie and Pfizer are reshaping their growth strategies as new drugs, acquisitions, pipelines and patent challenges shape their outlooks.

New model-based analysis further supports the potential of TECVAYLI (teclistamab-cqyv) plus DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma

New model-based analysis further supports the potential of TECVAYLI (teclistamab-cqyv) plus DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma New model-based analysis further supports the potential of...

JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania Study

J&J's Caplyta shows rapid and significant improvement in bipolar mania symptoms in a pivotal phase III study.

Johnson & Johnson May Offload Its Orthopedics Unit for $20 Billion -- and Investors Shouldn't Miss What That Could Signal

Key PointsJohnson & Johnson announced plans to spin off its orthopedics business in late 2025...

CAPLYTA (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study

CAPLYTA (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study CAPLYTA (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 studyPR NewswireTITUSVILLE, N.J., Sept. 21, 2026CAPLYTA significantly reduced the signs and...

Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?

AZN's pipeline setbacks weigh on its stock, but a deep late-stage pipeline and 20+ expected readouts offer key catalysts.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

LEGN’s New CEO From Novartis Paves Way For Buyout Speculation 

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

NewFutures

Fundamentals

Info

JNJ Futures

JNJ Single Stock Futures